内源性纤溶功能受损作为心血管风险新标志物:JACC综述解读
急性冠脉综合征患者中,用全血高剪切或血浆浊度法可检出内源性纤溶受损,其独立于传统危险因素且不受抗血小板治疗影响,是未来心血管风险的强标志物。该综述讨论了现有及在研药物对纤溶状态的调节作用,为改善ACS预后提供新思路。
要点
- 内源性纤溶受损是ACS患者未来心血管风险的独立强标志物。
- 全血高剪切或血浆浊度法可检测纤溶状态,不受抗血小板治疗影响。
- 检测纤溶功能有助于识别抗血小板治疗后仍高风险的ACS患者。
核心结论
- 内源性纤溶受损是独立于传统危险因素且不受抗血小板治疗影响的未来心血管风险强标志物,检测纤溶功能可识别抗血小板治疗后仍高风险的ACS患者。
研究设计与样本
- 综述(JACC Review Topic of the Week),汇总近期前瞻性研究,采用全血高剪切全局测定或血浆浊度法检测内源性纤溶。
主要发现
- 近期前瞻性研究显示,相当数量ACS患者可检出内源性纤溶受损,且为未来心血管风险的强标志物。
- 该标志物独立于传统心血管危险因素,且不受抗血小板治疗影响。
临床怎么用
- 可考虑用全血高剪切或血浆浊度法检测内源性纤溶,识别抗血小板治疗后仍高风险的ACS患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endogenous fibrinolysis is a powerful natural defense mechanism against lasting arterial thrombotic occlusion. Recent prospective studies have shown that impaired endogenous fibrinolysis (or hypofibrinolysis) can be detected in a significant number of patients with acute coronary syndrome (ACS) using global assays and is a strong marker of future cardiovascular risk. This novel risk biomarker is independent of traditional cardiovascular risk factors and unaffected by antiplatelet therapy. Most prospective prognostic data have been obtained using a global assay using native whole blood at high shear or plasma turbidimetric assays, which are described herein. Tests of endogenous fibrinolysis could be used to identify patients with ACS who, despite antiplatelet therapy, remain at high cardiovascular risk. This review discusses the impact of currently available medications and those in development that favorably modulate fibrinolytic status and may offer a potential new avenue to improve outcomes in ACS.
引用
- Gorog DA, Lip GYH. Impaired Spontaneous/Endogenous Fibrinolytic Status as New Cardiovascular Risk Factor?: JACC Review Topic of the Week. J Am Coll Cardiol. 2019. PMID: 31488274. doi:10.1016/j.jacc.2019.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。